We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > deucravacitinib

News List

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Plaque Psoriasis Accepted by FDA and Validated by European Medicines Agency AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for ...
BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
BMS’ deucravacitinib beats Otezla in psoriasis study pharmatimes
February 05, 2021
Bristol Myers Squibb’s investigative drug deucravacitinib has demonstrated positive results in a Phase III trial, including showing superiority over Amgen’s Otezla (apremilast).
Bristol Myers Squibb’s psoriasis med hits the mark in phase III pharmatimes
November 06, 2020
Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.